Skip navigation
Skip navigation

Anti-PD1 therapy in patients with metastatic melanoma: A single centre experience

Nguyen, Bella Hai; Robinson, E; Arora, A; Ali, Sayed


Background: The introduction of anti-PD1 checkpoint inhibitors: pembrolizumab and nivolumab has changed the treatment landscape of stage IV melanoma. Clinical trials reported response rates between 21% and 32%.2 Grade 3-4 adverse events ranged between 5% and 14%.1,2 A single-center experience of safety and efficacy of pembrolizumab, or nivolumab in treating stage IV melanoma were analyzed in this presentation. Methods: Records of patients from The Canberra Hospital between January 1,...[Show more]

CollectionsANU Research Publications
Date published: 2016
Type: Conference paper
Source: Asia-Pacific Journal of Clinical Oncology
DOI: 10.1111/ajco.12543


File Description SizeFormat Image
01_Nguyen_Anti-PD1_therapy_in_patients_2016.pdf47.26 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator